Sugi Predict

Sugi Predict / Compounds / SCHEMBL5267580

SCHEMBL5267580

SCHEMBL5267580

Nc1[nH]nc2ccncc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.37
▸ EP300 Q09472 1/20 0.37
▸ KAT2B Q92831 1/20 0.37
▸ KAT8 Q9H7Z6 1/20 0.37
▸ GAA P10253 4/20 0.37
▸ CDK7 P50613 3/20 0.37
▸ CDK9 P50750 3/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ CCNT1 O60563 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CDK4 P11802 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCND1 P24385 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ CCNH P51946 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ DYRK1A Q13627 3/20 0.36
▸ JAK2 O60674 3/20 0.36
▸ CHEK1 O14757 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375092 0.83 KDM4C (0.39) AXLEP300KAT2BKAT8GAA
SCHEMBL31167697 0.75 CYP1A2 (0.55) AXLEP300KAT2BKAT8CDK7
SCHEMBL15233163 0.75 PIM1 (0.54) CDK7CDK9CDK1CDK2MAPT
SCHEMBL11882019 0.74 CLK1 (0.42) GAACDK7CDK9KMT2ACCNT1
SCHEMBL5772250 0.72 CCNA2 (0.45) CDK7CDK9KMT2ACDK2MAPT
SCHEMBL1100756 0.71 CYP1A2 (0.56) GAACDK9KMT2ACCNT1CDK1
SCHEMBL25952897 0.71 PRKAA1 (0.37) CDK7CDK9CCNT1CDK2MAPT
SCHEMBL21672123 0.71 PIM1 (0.36) CDK7CDK9MAPTDYRK1AJAK2
SCHEMBL27529888 0.71 ERN1 (0.34) CDK7CDK9CCNT1CDK1DYRK1A
SCHEMBL8142848 0.69 AURKA (0.45) GAACDK7CDK9CDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2026-03-26 — — US disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 — — US disclosed
US-20240279240-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-08-22 — — US disclosed
EP-2976340-B1 CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-06-13 — — EP disclosed
EP-1845978-A1 SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE Aventis Pharma S.A. (FR) 2007-10-24 — — EP disclosed
WO-2006077319-A1 SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AVENTIS PHARMA S.A. (FR) 2006-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 AXL 249/4885EP300 1562/4885KAT2B 1733/4885
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK1, JAK3 AXL 362/4885EP300 3265/4885KAT2B 3770/4885
US-20240279240-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK3, JAK1 AXL 259/4885EP300 2146/4885KAT2B 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.